Hypera approves BRL 185 million interest payment: dividend per Hypera stock is BRL 0.26

Published on 10/16/2026 at 01:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

A BRL 0.26304 per-share payment was declared on September 23, 2026. Hypera stock also draws a BRL 480 million 2027 Semavy forecast.

Hypera payout and product forecasts

Hypera approved BRL 185 million in interest on equity on September 23, 2026.
Semavy could generate BRL 480 million in revenue during 2027, according to Itaú BBA.
Hypera set October 5, 2026 as the deadline for qualifying tax documents.

Hypera, BRHYPEACNOR0, Illustration mit AI erstellt.

Hypera approved BRL 185 million in interest on equity on September 23, 2026, including BRL 0.26304 per ordinary share, according to Eu Quero Investir. The payment adds a defined shareholder-return event to the company's latest operating picture.

Hypera combines payout with Semavy plans

The payout followed a second-quarter 2026 in which revenue reached BRL 2.34 billion and net income stood at BRL 490.24 million. The figures were also highlighted in the company's recent coverage, while the B3 listing and the HYPE3 ticker identify the Brazilian pharmaceutical issuer.

Product expectations provide the main growth angle. InfoMoney reported on September 15, 2026 that Itaú BBA estimated an initial Semavy order of 400,000 pens could support BRL 75 million in gross revenue in each of the third and fourth quarters of 2026, followed by BRL 120 million per quarter in 2027.

What could Semavy add to revenue?

The same analysis put the 2027 revenue opportunity at BRL 480 million and cited a base-case estimate of BRL 400 million in additional revenue plus BRL 60 million in additional EBITDA. XP Investimentos estimated that Semavy could add between 1 percent and 8 percent to Hypera's 2027 revenue, while Itaú BBA projected BRL 1.1 billion in shareholder free cash flow for 2026.

Three dated steps explain the payout

On September 15, 2026, InfoMoney reported the Itaú BBA and XP views on Semavy and Hypera's valuation. On September 23, 2026, the board approved BRL 185 million in interest on equity, according to Eu Quero Investir. On September 29, 2026, the shares began trading ex-interest on equity, with the entitlement tied to the September 28, 2026 record date.

Next date for the payment

The stated schedule set October 5, 2026 as the deadline for qualifying tax documents, while payment was listed for December 31, 2027. The company also said the interest on equity would count toward any dividends declared for fiscal year 2026.

Hypera keeps income and growth linked

Hypera's latest investor case therefore rests on two measurable elements: a BRL 0.26304 per-share distribution and a Semavy revenue scenario reaching BRL 480 million in 2027. The balance between near-term cash returns and the cost of launching the product remains central to the earnings discussion.

Hypera is listed on B3 under ticker HYPE3 and operates in the pharmaceutical sector, according to Global Banking & Finance Review.